Ask AI
Obesity Management During Reproductive Years
Clinical Queries: Expert Insights to Improve Obesity Management During Reproductive Years 

Released: January 20, 2026

Activity

Progress
1
Course Completed

  1. American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 8: Interpregnancy care. Obstet Gynecol. 2019;133:e51-e72.
  2. Duah J, Seiger DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025;23:2.
  3. Ogunwole SM, Chen S, Mitta S, et al. Interconception care for primary care providers: consensus recommendations on preconception and postpartum management of reproductive-age patients with medical comorbidities. Mayo Clin Proc Innov Qual Outcomes. 2021;5:872-890.
  4. Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10:396-408.
  5. Barrett TS, Hafermann JO, Richards S, et al. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg. 2025;160:1232-1239.
  6. Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2021;116:1266-1285. 
  7. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36. 
  8. Semaglutide (prescribing information). Plainsboro, NJ: Novo Nordisk; 2025.
  9. Tirzepatide (prescribing information). Indianapolis, IN: Lilly; 2025.
  10. Nuako A, Tu L, Reyes KJC, et al. Pharmacologic treatment of obesity in reproductive aged women. Curr Obstet Gynecol Rep. 2023;12:138-146.
  11. Phentermine and topiramate extended-release capsules (prescribing information). Winchester, KY” Vivus; 2024.
  12. Tirzepatide [product information]. Firenze, Italy: Eli Lilly Italia S.p.A.; 2024.
  13. Tirzepatide [product information]. Toronto, Canada: Eli Lilly Canada Inc.; 2025.
  14. Maya J, Pant D, Fu Y, et al. Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025:e2520951.

 

Continue the activity for another interactive case.